Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL25291849 | 0.98 | ALDH1A1 (0.53) | ALDH1A1ADRB3ADRB1IRAK4KEAP1 | |
| SCHEMBL30628275 | 0.88 | IRAK4 (0.46) | ALDH1A1ADRB3ADRB1IRAK4MKNK1 | |
| SCHEMBL4275478 | 0.88 | IRAK4 (0.46) | ALDH1A1ADRB3ADRB1IRAK4MKNK1 | |
| SCHEMBL28091356 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ADRB3ADRB1IRAK4KEAP1 | |
| SCHEMBL20231752 | 0.84 | KEAP1 (0.46) | ALDH1A1KEAP1KDM4EHPGDHSD17B10 | |
| SCHEMBL25793610 | 0.83 | FFAR4 (0.50) | ALDH1A1IRAK4KDM4EMKNK1MKNK2 | |
| SCHEMBL20818564 | 0.83 | CA12 (0.49) | ALDH1A1IRAK4KDM4EHPGDHSD17B10 | |
| SCHEMBL17908039 | 0.82 | ALDH1A1 (0.73) | ALDH1A1ADRB3ADRB1IRAK4KDM4E | |
| SCHEMBL25253624 | 0.82 | IRAK4 (0.41) | ALDH1A1ADRB3ADRB1IRAK4MKNK1 | |
| SCHEMBL4776570 | 0.81 | ALDH1A1 (0.56) | ALDH1A1ADRB3ADRB1IRAK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025010392-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025010394-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF INFLAMMATORY CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4457213-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | Psy Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-118574807-A | Inhibition of monoacylglycerol lipase (MAGL) | PSY治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023130023-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023130050-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023130050-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023130043-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | ALDH1A1 1923/4885ADRB3 3221/4885ADRB1 2916/4885 |
| US-20250084065-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LPL | ALDH1A1 762/4885ADRB3 1667/4885ADRB1 1470/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | ALDH1A1 1923/4885ADRB3 3221/4885ADRB1 2916/4885 |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | ALDH1A1 1116/4885ADRB3 1071/4885ADRB1 1209/4885 |
| US-20250170100-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | ALDH1A1 1075/4885ADRB3 897/4885ADRB1 744/4885 |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | ALDH1A1 1923/4885ADRB3 3221/4885ADRB1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.